4 edition of significance of genetic-based factors for prostate cancer progression found in the catalog.
significance of genetic-based factors for prostate cancer progression
Robert K. Nam
Thesis (M.Sc.) -- University of Toronto, 1999.
|Series||Canadian theses = -- Thèses canadiennes|
|The Physical Object|
|Pagination||2 microfiches : negative. --|
A high-fiber diet works to reduce hormone levels that may be involved in the progression of prostate cancer. One study indicated that a high-fiber, low-fat diet followed only for 10 days resulted in serum changes that reduced the growth of prostate :// INTRODUCTION. Prostate cancer is the second most common cancer in men worldwide, with over million cases and , deaths annually, according to data from the GLOBOCAN database. If completely localized within the capsule of the gland, some favorable-risk prostate cancers can be managed with active surveillance or potentially cured by definitive local therapy (eg, radical
Background. The Gleason grading system developed by Dr. Donald Gleason in , remains the cornerstone for the management of prostate cancer (PCa). 1, 3 The system is relatively simple and reasonably reproducible to apply. It is one of the key parameters for therapy‐planning (active surveillance vs definitive therapy), and remains as the most important prognostic factor in predicting Purpose Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. Patients and Methods A cohort of patients with prostate cancer treated with ADT was genotyped for SLCO2B1
1 Current Issues in Pathologic Evaluation Epidemiology of and Risk Factors for Prostate Cancer: Diet, Genetics, and Racial Variation Molecular Genetics and Markers of Progression Screening for Prostate Cancer Trends in Diagnosis, Biopsy, and Imaging A Current Synthesis of the Management of Prostate Cancer: When Is Objective: Here we are aiming to gain insights into the genetic associations of prostate cancer through a network-based systems approach using the BC3Net algorithm. Methods: Specifically, we infer a prostate cancer Gene Regulatory Network (GRN) from a large-scale gene expression data set of patient RNA-seq profiles obtained from The Cancer
Hampton, Hampton National Historic Site, Maryland
Sketches of a summer trip to New York and the Canadas
inquiry into successful exporting
Stillness of storm
Understanding human sexuality
The fire at Greycombe farm
Law, city, and king
D. M. Cook.
Relaxation from steady states far from equilibrium and the persistence of anomalous shock behavior in weakly ionized gases
The history of the effects of religion on mankind
British watercolors, 1750-1850
revised statutes of Canada, 1927.
Briefcase Bible Cover
Justice 2 Committee
Significance of Genetic-Based Factors significance of genetic-based factors for prostate cancer progression book Prostate Cancer Progression. Masters of Science (CIinical Epidemiology) Robert K.
Nam Comrnunity Heaith University of Toronto Objectives: To establis h whether pol ymorphisms of the androgen receptor, SRD5A2 and CYP3A4 enzyme genes are important prognostic factors for prostate cancer :// CYP17A1, HSD17B2, and ESR1 could be candidate prognostic factors for prostate cancer progression in different ethnic groups and even in different disease stages.
SLCO2B1 and SLCO1B3 Wright et al7 studied the efﬁcacy of ADT in prostate cancer patients through genetic variation in SLCO1B3 and SLCO2B1. The Prostate cancer risk and genetics. PCa is now the commonest cancer in men in the Western world (Cancer Research UK Factsheets, ).
However, its etiology remains poorly understood and no definite lifestyle risk factors have been :// The identification of risk factors for this cancer is therefore based on the evaluation of populations recognized through epidemiological studies as being at a unique risk level.
Such studies have produced certain demographic, dietary, genetic, histological, and biochemical features that identify patients at an elevated risk for prostate :// Lange EM () Identification of genetic risk factors for prostate cancer: analytic approaches using hereditary prostate cancer families.
In: Foulkes WD, Cooney KA (eds) Male reproductive cancers; epidemilogy, pathology and genetics, Springer, New York Google Scholar PTEN, a tumor suppressor gene encoding a phosphatase active against both proteins and lipid substrates, appears to be a common target for somatic alteration during prostate cancer progression.
PTEN is an inhibitor of the phosphatidylinositol 3′-kinase/protein kinase B (PI3K/Akt) signaling pathway needed for cell cycle progression and Omega-3 and -6 PUFAs differentially modulate prostate tumor weight in Pten P–/– mice. Mice with a defined genetic lesion, in this case loss of the tumor suppressor gene Pten, develop cancer determine whether genetic cancer risk can be modified by dietary factors, wild-type mice and mice with Pten deletion were fed diets with different amounts of omega-3 and omega-6 fatty Emerging recommendations and guidelines for genetic counseling referrals are based on prostate cancer age and stage at diagnosis and specific family cancer history patterns.[38,39] For a summary of the current criteria for genetic testing in men with or at risk of prostate cancer Timothy J.
Key, in Vegetarian and Plant-Based Diets in Health and Disease Prevention, 13 Prostate Cancer. Little is known about the etiology of prostate cancer, and the only well-established risk factors are increasing age, family history, black ethnic background, and genetic ical studies suggest that risk may be positively associated with a Western-style diet, and diets In relation to these risk factors, advanced stage at diagnosis was a good surrogate for fatal prostate cancer, but high‐grade (Gleason ≥ 7 or Gleason ≥ 8) was not.
Only for high calcium intake was there a close correspondence for associations among high‐grade cancer, advanced and fatal prostate :// The modern research on molecular basis of prostate cancer (PCa) development includes studies aiming to identify potential genetic markers which could be used in diagnostics and/or monitoring of PCa.
Genome-wide association studies (GWASs) have identified over 75 variants associated with PCa risk. One of the major PCa-related regions identified through GWASs is found to be a segment of 8q The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer.
Highlighting the latest major advances in the field, the book includes chapters on the most controversial areas of prostate cancer – screening, chemoprevention, and active › Books › New, Used & Rental Textbooks › Medicine & Health Sciences.
Since its discovery, elevated prostate-specific antigen (PSA) has been the measurement to indicate possibility of prostate cancer, as well as biochemical recurrence following treatment. Although PSA has led to decrease in prostate cancer–related mortalities, PSA is a nonspecific prostate cancer biomarker reflective of other prostate-related conditions such as benign prostatic hyperplasia /biomarkers-for-diagnosis-and-prognosis-of-prostate-cancer.
Identification of Genetic Markers for Prostatic Cancer Progression Article (PDF Available) in Laboratory Investigation 80(6) July with 72 Reads How we measure 'reads' Looking at known genetic factors, family history of prostate cancer is a recognized risk factor for prostate cancer [, ].
Men with prostate cancer in the family appear to have doubled the /_Unravelling_the_genetics_of_prostate_cancer. The genes that influence prostate cancer progression remain largely unknown.
Since the carboxylesterase gene family plays a crucial role in xenobiotic metabolism and lipid/cholesterol homeostasis, we hypothesize that genetic variants in carboxylesterase genes may influence clinical outcomes for prostate cancer patients.
A total of (36 genotyped and imputed) single The diverse implications of genetic testing on prostate cancer management have spurred several guidance documents on genetic testing.
24,40 The recently published consensus document recommends genetic testing for men with prostate cancer who have strong family histories (e.g. hereditary breast and ovarian cancer syndrome, hereditary prostate / Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription factor.
We generated Based on the results of those studies, genetic models for tumor progression have been constructed in various types of human cancers in association with accumulation of genetic alterations in cancer cells. Such a genetic model was first demonstrated on colorectal carcinoma, since tumors in various stages of progression, from small adenomas to The Epidemiology of Prostate Cancer (D T Bishop) Genetic Aberrations in Prostate Tumours Growth Factors in Prostatic Development (A A Thomson et al.) The Prostate and Cancer: An Introduction to Normal Morphology and Histopathology for Bcl-2 Family Proteins and Prostate Cancer Progression: Potential for Therapeutic Interventions.
Khurram. Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med (21):[PUBMED Abstract] Winawer S, Fletcher R, Rex D, et al.: Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.
Gastroenterology (2):Men with prostate cancer often have elevated PSA levels because the cancer cells make excessive amounts of this protein. At the time of initial diagnosis of prostate cancer, the PSA level helps determine how likely it is that the cancer has spread (metastasized).
Keywords:prostate cancer, animal model, tissue-specific promoters, prostate epithelium-specific gene inactivation, growth factors, retinoid receptors, tumor suppressors.
Abstract: Animal models of prostate cancer have been limited in number and in relevance to the human disease. With the advancement of transgenic and knockout technologies